Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VERTEX PHARMACEUTICALS

(VRTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sector Update: Health Care Stocks Roughed Up Heading into Friday Close

06/11/2021 | 03:58pm EDT


ę MT Newswires 2021
All news about VERTEX PHARMACEUTICALS
10:25aVERTEX PHARMACEUTICALS : UBS Adjusts Vertex Pharmaceuticals' Price Target to $25..
MT
07/30VERTEX PHARMACEUTICALS : MA Management's Discussion and Analysis of Financial Co..
AQ
07/30VERTEX PHARMACEUTICALS : Morgan Stanley Adjusts Vertex Pharmaceuticals' Price Ta..
MT
07/30VERTEX PHARMACEUTICALS : SVB Leerink Adjusts Vertex Pharmaceuticals' Price Targe..
MT
07/30VERTEX PHARMACEUTICALS : Goldman Sachs Adjusts Price Target on Vertex Pharmaceut..
MT
07/30VERTEX PHARMACEUTICALS : JPMorgan Adjusts Price Target on Vertex Pharmaceuticals..
MT
07/30VERTEX PHARMACEUTICALS : Piper Sandler Adjusts Price Target on Vertex Pharmaceut..
MT
07/30VERTEX PHARMACEUTICALS : RBC Lifts Price Target on Vertex Pharmaceuticals to $24..
MT
07/29VERTEX PHARMACEUTICALS : Phase 3 study of next-in-class triple combination for C..
PU
07/29VERTEX PHARMACEUTICALS : Q2 Adjusted EPS, Revenue Increase YOY; Raises 2021 Guid..
MT
More news
Financials (USD)
Sales 2021 7 244 M - -
Net income 2021 2 082 M - -
Net cash 2021 8 095 M - -
P/E ratio 2021 25,1x
Yield 2021 -
Capitalization 52 296 M 52 296 M -
EV / Sales 2021 6,10x
EV / Sales 2022 5,07x
Nbr of Employees 3 400
Free-Float 99,8%
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 201,58 $
Average target price 263,30 $
Spread / Average Target 30,6%
EPS Revisions
Managers and Directors
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
VERTEX PHARMACEUTICALS-14.71%52 296
GILEAD SCIENCES, INC.17.22%85 648
BIONTECH SE302.78%79 303
WUXI APPTEC CO., LTD.36.10%59 516
REGENERON PHARMACEUTICALS18.94%59 505
GENMAB A/S15.10%29 546